Memorial Sloan-Kettering Cancer Center (MSKCC) is the largerst privately owneed nonprofit cancer center in the world. The Center consists of 3 corporations. Memorial Hospital for Cancer and Allied Diseases, foundin in 1884 is the clinical unit;Sloan-Kettering Institute for Cancer Research, founded in 1945 is the basic research unit;and Memorial Sloan-Kettering Cancer Center, founded in 1960 is the unit that formulates policies and long-range plans and coordinates the activities of the hospital and the institute. MSKCC is a free-standing institution committed to exceptional in-patient and out-patient care, leading edge research and superb clinical and research training programs. MSKCC's clinical research programs are synonymous with those of the Cancer and Leukemia Group B (CALGB). Physician-scientists at MSKCC hold leadership positions in the CALGB across an array of disease-specific areas and treatment modalities, with significant administrative responsibilities for the group. Scientific and clinical research programs at MSKCC are created with the intention of ultimately testing them, when possible, in the larger patient populations offered by our participation in the CALGB. During the next six years, MSKCC will continue to expand its clinical and research facilities as well as its research and training programs. The enclosed grant offers examples of MSKCC contributions to the success of the CALGB and support for MSKCC's continued participation.
MSKCC's research programs are specifically designed to utilize the large patient population and broad, multi-disciplinary staff of clinical and laboratory based investigators while stimulating the application of discoveries in the basic sciences to promote the prevention, detection, diagnosis and treatment of many forms of cancer.
|Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89|
|Shulman, Lawrence N; Berry, Donald A; Cirrincione, Constance T et al. (2014) Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol 32:2311-7|
|Ruddy, Kathryn J; O'Neill, Anne; Miller, Kathy D et al. (2014) Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. Breast Cancer Res Treat 144:591-7|
|Roman, Michael A; Koelwyn, Graeme J; Eves, Neil D et al. (2014) Comparison of performance status with peak oxygen consumption in operable patients with non-small-cell lung cancer. Respirology 19:105-8|
|Shiovitz, Stacey; Bertagnolli, Monica M; Renfro, Lindsay A et al. (2014) CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology 147:637-45|
|Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50|
|Herndon 2nd, James E; Kornblith, Alice B; Holland, Jimmie C et al. (2013) Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials. Psychooncology 22:315-23|
|Lewis, Lionel D; Miller, Antonius A; Owzar, Kouros et al. (2013) The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics 23:29-33|
|Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43|
|Iyengar, Neil M; Hudis, Clifford A; Gucalp, Ayca (2013) Omega-3 fatty acids for the prevention of breast cancer: an update and state of the science. Curr Breast Cancer Rep 5:247-254|
Showing the most recent 10 out of 68 publications